DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drocourt, L.
Right arrow Articles by Vilarem, M.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drocourt, L.
Right arrow Articles by Vilarem, M.-J.

Vol. 29, Issue 10, 1325-1331, October 2001

Calcium Channel Modulators of the Dihydropyridine Family Are Human Pregnane X Receptor Activators and Inducers of CYP3A, CYP2B, and CYP2C in Human Hepatocytes

Lionel Drocourt, Jean-Marc Pascussi, Eric Assenat, Jean-Michel Fabre, Patrick Maurel, and Marie-José Vilarem

Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Montpellier, France (L.D., J.-M.P., E.A., P.M., M.-J.V); and Service de Chirurgie, Hopital Saint Eloi, Montpellier, France (J.-M.F.)

The expression of three cytochromes P450 (CYP3A4, CYP2C9, and CYP2B6) was investigated in primary human hepatocyte cultures following treatment with four calcium channel modulators (CCM) of the dihydropyridine family, three antagonists (nifedipine, nicardipine, and isradipine), and one agonist (BK8644). Induction of CYP3A4 was studied by Northern blot, Western blot, and enzymatic activity. Induction began between 1 and 10 µM CCM and was dependent on the presence of dexamethasone (100 nM) in the medium. CYP3A4 mRNA accumulation started only after 16 h of treatment because pregnane X receptor (hPXR) synthesis was needed. Cotransfection experiments showed that the proximal and the distal PXR response elements of the CYP3A4 promoter and hPXR (HepG2 cells) or dexamethasone-induced hPXR (primary hepatocytes) were necessary to obtain full induction. Furthermore, glutathione S-transferase pull-down assays demonstrated that the CCM tested can act as hPXR ligands. In addition, cotransfection experiments in CV1 cells showed that these compounds failed to reverse CAR (constitutively activated receptor) inactivation by androstenol. Finally, 10 µM CCM induced both CYP2C9 and CYP2B6, strengthening the evidence that hPXR is involved in the regulation of these genes. All together, these results widen the field of hPXR activators to a new class of ligand, namely the CCM of the dihydropyridine family.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
T. Toriyabe, K. Nagata, T. Takada, Y. Aratsu, T. Matsubara, K. Yoshinari, and Y. Yamazoe
Unveiling a New Essential Cis Element for the Transactivation of the CYP3A4 Gene by Xenobiotics
Mol. Pharmacol., March 1, 2009; 75(3): 677 - 684.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. L. Howarth, S. H. W. Law, B. Barnes, J. M. Hall, D. E. Hinton, L. Moore, J. M. Maglich, J. T. Moore, and S. W. Kullman
Paralogous Vitamin D Receptors in Teleosts: Transition of Nuclear Receptor Function
Endocrinology, May 1, 2008; 149(5): 2411 - 2422.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Ekins, C. Chang, S. Mani, M. D. Krasowski, E. J. Reschly, M. Iyer, V. Kholodovych, N. Ai, W. J. Welsh, M. Sinz, et al.
Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites
Mol. Pharmacol., September 1, 2007; 72(3): 592 - 603.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
B. L. Urquhart, R. G. Tirona, and R. B. Kim
Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs
J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. R. Faucette, T.-C. Zhang, R. Moore, T. Sueyoshi, C. J. Omiecinski, E. L. LeCluyse, M. Negishi, and H. Wang
Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 72 - 80.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. L. Ripp, J. B. Mills, O. A. Fahmi, K. A. Trevena, J. L. Liras, T. S. Maurer, and S. M. de Morais
Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction
Drug Metab. Dispos., October 1, 2006; 34(10): 1742 - 1748.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. G. Zhang, S. S. Dehal, T. Ho, J. Johnson, C. Chandler, A. P. Blanchard, R. J. Clark Jr., C. L. Crespi, D. M. Stresser, and J. Wong
HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81
Drug Metab. Dispos., May 1, 2006; 34(5): 734 - 737.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Anapolsky, S. Teng, S. Dixit, and M. Piquette-Miller
THE ROLE OF PREGNANE X RECEPTOR IN 2-ACETYLAMINOFLUORENE-MEDIATED INDUCTION OF DRUG TRANSPORT AND -METABOLIZING ENZYMES IN MICE
Drug Metab. Dispos., March 1, 2006; 34(3): 405 - 409.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Katoh, T. Matsui, M. Nakajima, C. Tateno, Y. Soeno, T. Horie, K. Iwasaki, K. Yoshizato, and T. Yokoi
IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER
Drug Metab. Dispos., June 1, 2005; 33(6): 754 - 763.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Sahi, R. H. Stern, M. A. Milad, K. A. Rose, G. Gibson, X. Zheng, L. Stilgenbauer, N. Sadagopan, S. Jolley, D. Gilbert, et al.
EFFECTS OF AVASIMIBE ON CYTOCHROME P450 2C9 EXPRESSION IN VITRO AND IN VIVO
Drug Metab. Dispos., December 1, 2004; 32(12): 1370 - 1376.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. Zhou, M. M. Tabb, A. Sadatrafiei, F. Grun, and B. Blumberg
TOCOTRIENOLS ACTIVATE THE STEROID AND XENOBIOTIC RECEPTOR, SXR, AND SELECTIVELY REGULATE EXPRESSION OF ITS TARGET GENES
Drug Metab. Dispos., October 1, 2004; 32(10): 1075 - 1082.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. R. Faucette, H. Wang, G. A. Hamilton, S. L. Jolley, D. Gilbert, C. Lindley, B. Yan, M. Negishi, and E. L. LeCluyse
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Drug Metab. Dispos., March 1, 2004; 32(3): 348 - 358.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
C. Handschin and U. A. Meyer
Induction of Drug Metabolism: The Role of Nuclear Receptors
Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. A. Kliewer, B. Goodwin, and T. M. Willson
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Endocr. Rev., October 1, 2002; 23(5): 687 - 702.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Burk, H. Tegude, I. Koch, E. Hustert, R. Wolbold, H. Glaeser, K. Klein, M. F. Fromm, A. K. Nuessler, P. Neuhaus, et al.
Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine
J. Biol. Chem., June 28, 2002; 277(27): 24280 - 24288.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. C. Zangar, A. L. Kimzey, J. R. Okita, D. S. Wunschel, R. J. Edwards, H. Kim, and R. T. Okita
Cytochrome P450 3A Conjugation to Ubiquitin in a Process Distinct from Classical Ubiquitination Pathway
Mol. Pharmacol., April 1, 2002; 61(4): 892 - 904.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.